PHAR News

Pharming to participate in fireside chat at Jefferies Global Healthcare Conference in London

MHRA approves Pharming’s Joenja® (leniolisib) as first treatment specifically for children with APDS in the U.K.

Pharming Group announces third quarter 2026 revenues above market expectations

Pharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026

Pharming announces CEO transition

Pharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja® to treat children with APDS

Pharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026

FDA approves Pharming’s Joenja® as first treatment for children with APDS in the U.S.

Pharming Group to participate in September investor conferences

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Bronstein, Gewirtz & Grossman, LLC (PHAR) And Encourages Stockholders to Reach Out